Effects of 8-prenylnaringenin on the hypothalamo-pituitary-uterine axis in rats after 3-month treatment.
Phytoestrogens are increasingly consumed in artificially high doses as herbal preparations and nutritional supplements. The flavanone 8-prenylnaringenin (8PN) is a potent phytoestrogen, but its benefits and risks after long-term application are poorly identified. Therefore, we tested two doses of 8PN and 17beta-estradiol-3-benzoate (E2B) (effective doses: 6.8 and 68.4 mg/kg body weight (BW) of 8PN, and 0.17 and 0.7 mg/kg BW of 17beta-estradiol (E2)) and compared their effects on uterine weight, pituitary hormones (LH, FSH and prolactin) and the expression of estrogen-regulated genes and of estrogen receptor (ER)alpha and ERbeta in the hypothalamus, pituitary and uterus. Both doses of E2 and the high dose of 8PN suppressed serum LH and FSH, and stimulated serum prolactin levels, uterine weight, and progesterone receptor, insulin-like growth factor I and complement protein C3 mRNA transcripts. In the preoptic and the mediobasal areas of the hypothalamus, all treatments had negligible effects on ERalpha and ERbeta and gonadotropin-releasing hormone (GnRH) receptor gene expression, while ERbeta and GnRH receptor transcripts in the anterior pituitary were reduced under both E2 doses and the high 8PN dose. The mRNA concentrations of the LHalpha and -beta subunits in the pituitary were suppressed by E2 and 8PN. In summary, 8PN had very similar though milder effects than E2 on all tested parameters. Inhibition of climacteric complaints by E2 takes place in the hypothalamus, where it inhibits the overactive GnRH pulse generator. Hence, 8PN may be used to inhibit climacteric symptoms effectively. Human pharmacologic studies will show whether the stimulatory effect on the uterus that was found in the present animal model would require the concomitant administration of progestins to prevent endometrial overstimulation.
Christoffel
J
J
Division of Clinical and Experimental Endocrinology, Department of Obstetrics and Gynecology, University of Göttingen, Robert-Koch-Str 40, 37099 Göttingen, Germany.
Rimoldi
G
G
Wuttke
W
W
D000818:Animals; D001682:Biological Availability; D003176:Complement C3 / Q000235:genetics; D019587:Dietary Supplements; D004305:Dose-Response Relationship, Drug; D004958:Estradiol / Q000494:pharmacology; D047628:Estrogen Receptor alpha / Q000032:analysis; D047629:Estrogen Receptor beta / Q000032:analysis; D005260:Female; D044950:Flavanones / Q000494:pharmacology*; D007987:Gonadotropin-Releasing Hormone / Q000097:blood / Q000235:genetics; D006065:Gonadotropins, Pituitary / Q000097:blood / Q000235:genetics; D007031:Hypothalamus / Q000737:chemistry / Q000187:drug effects*; D007334:Insulin-Like Growth Factor I / Q000235:genetics; D009929:Organ Size / Q000187:drug effects; D010052:Ovariectomy; D010903:Pituitary Gland, Anterior / Q000737:chemistry / Q000187:drug effects*; D011388:Prolactin / Q000097:blood; D012333:RNA, Messenger / Q000032:analysis; D051381:Rats; D017207:Rats, Sprague-Dawley; D011966:Receptors, LHRH / Q000032:analysis / Q000235:genetics; D011980:Receptors, Progesterone / Q000235:genetics; D020133:Reverse Transcriptase Polymerase Chain Reaction; D013268:Stimulation, Chemical; D013997:Time Factors; D014599:Uterus / Q000737:chemistry / Q000187:drug effects*
C119737:8-prenylnaringenin; D003176:Complement C3; D047628:Estrogen Receptor alpha; D047629:Estrogen Receptor beta; D044950:Flavanones; D006065:Gonadotropins, Pituitary; D012333:RNA, Messenger; D011966:Receptors, LHRH; D011980:Receptors, Progesterone; D007987:Gonadotropin-Releasing Hormone; D004958:Estradiol; D007334:Insulin-Like Growth Factor I; D011388:Prolactin